Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,559 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study.
Tezuka T, Hamada C, Ishida H, Ooshiro M, Matsuoka H, Kawasaki S, Mishima H, Maeda K, Sakamoto J, Koda K. Tezuka T, et al. Among authors: ishida h. Invest New Drugs. 2013 Oct;31(5):1321-9. doi: 10.1007/s10637-013-9982-3. Epub 2013 Jul 2. Invest New Drugs. 2013. PMID: 23817973 Free PMC article. Clinical Trial.
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Kato T, Mishima H, Ikenaga M, Murata K, Ishida H, Fukunaga M, Ota H, Tominaga S, Ohnishi T, Amano M, Ikeda K, Ikeda M, Sekimoto M, Sakamoto J, Monden M. Kato T, et al. Among authors: ishida h. Cancer Chemother Pharmacol. 2008 Feb;61(2):275-81. doi: 10.1007/s00280-007-0471-2. Epub 2007 Apr 11. Cancer Chemother Pharmacol. 2008. PMID: 17429630 Clinical Trial.
Multicenter phase II study of irinotecan plus bolus fluorouracil/l-leucovorin for metastasic colorectal cancer.
Mishima H, Ikenaga M, Ishida H, Iwamoto S, Morimoto T, Narahara H, Kato T, Tsujie M, Kitai T, Fukunaga M, Nakanishi M, Tsujinaka T, Furukawa H, Taguchi T; Osaka Gastrointestional Cancer Chemotherapy Study Group. Mishima H, et al. Among authors: ishida h. Anticancer Res. 2007 Mar-Apr;27(2):1003-8. Anticancer Res. 2007. PMID: 17465234 Free article. Clinical Trial.
Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
Tsutsumi S, Ishibashi K, Uchida N, Ojima H, Hosouchi Y, Yashuda N, Kigure W, Yamauchi S, Asao T, Ishida H, Kuwano H. Tsutsumi S, et al. Among authors: ishida h. Oncology. 2012;83(3):151-7. doi: 10.1159/000337992. Epub 2012 Aug 7. Oncology. 2012. PMID: 22889925 Clinical Trial.
[Clinical outcomes in refractory colorectal cancer patients with wild-type K-ras treated with bevacizumab and oxaliplatin-based chemotherapy as a first-line treatment].
Imaizumi H, Ishibashi K, Okada N, Tajima Y, Amano K, Hatano S, Kuwabara K, Sobajima J, Ishiguro T, Ohsawa T, Kumamoto K, Kumagai Y, Haga N, Ishida H. Imaizumi H, et al. Among authors: ishida h. Gan To Kagaku Ryoho. 2012 Nov;39(12):2185-8. Gan To Kagaku Ryoho. 2012. PMID: 23268018 Japanese.
3,559 results